Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma

Table 1 Clinical information of patients in high and low protein tyrosine phosphatase non-receptor 2 expression groups from The Cancer Genome Atlas database

Characteristic	Low expression (n = 185)	High expression (n = 185)
T stage, n (%)
T1	96 (51.9)	85 (45.9)
T2	46 (24.9)	47 (25.4)
T3	35 (18.9)	45 (24.4)
T4	6 (3.2)	8 (4.3)
Unknown	2 (1.1)	0 (0)
N stage, n (%)
N0	126 (68.1)	126 (68.1)
N1	21 (11.4)	3 (1.6)
N2-3	38 (20.5)	56 (30.3)
M stage, n (%)
M0	135 (73)	131 (70.8)
M1	22 (11.9)	22 (11.9)
MX	28 (15.1)	32 (17.3)
Clinical stage, n (%)
I	91 (49.2)	80 (43.2)
II	43 (23.2)	42 (22.7)
III	38 (20.6)	47 (25.4)
IV	3 (1.6)	2 (1.1)
Unknown	10 (5.4)	14 (7.6)
Age, n (%)
≤ 65 years	105 (56.8)	127 (68.6)
> 65 years	80 (43.2)	58 (31.4)
Unknown	0 (0)	0 (0)
Sex, n (%)
Female	46 (24.9)	75 (40.5)
Male	139 (75.1)	110 (59.5)
Unknown	0 (0)	0 (0)
Grade, n (%)
G1	33 (17.8)	22 (11.9)
G2	92 (49.7)	85 (46.0)
G3	54 (29.2)	67 (36.2)
G4	4 (2.2)	8 (4.3)
Unknown	2 (1.1)	3 (1.6)